Therapy News and Research

RSS

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.

30 Jun 2014

Complete analysis of regenerative medicine market

According to a new market research report by Allied Market Research titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020).

30 Jun 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

MagForce publishes operative highlights and financial results for fiscal year 2013

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the fiscal year ending on December 31, 2013 and operative highlights.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

ALS stands for Amyotrophic Lateral Sclerosis, better known as “Lou Gehrig’s Disease”. It is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord.

30 Jun 2014

Modified classification system finds over one-third of knee replacements as inappropriate

New research reports that more than one third of total knee replacements in the U.S. were classified as "inappropriate" using a patient classification system developed and validated in Spain. The study, published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), highlights the need for consensus on patient selection criteria among U.S. medical professionals treating those with the potential need of knee replacement surgery.

30 Jun 2014

Single gene defines difference between aggressive and non-aggressive forms of thymoma

For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that doesn't require extensive therapy.

30 Jun 2014

New concussion therapy program for NFL members

Upledger Institute Clinic in conjunction with the Ricky Williams Foundation announced today the launch of their concussion therapy pilot program aimed at treating current and former members of the NFL.

28 Jun 2014

Host-directed therapy: A new type of TB treatment

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy.

28 Jun 2014

Targeting ASIC-related neurotransmission may lead to new therapies for treating drug addiction

University of Iowa researchers have discovered a new form of neurotransmission that influences the long-lasting memory created by addictive drugs, like cocaine and opioids, and the subsequent craving for these drugs of abuse. Loss of this type of neurotransmission creates changes in brains cells that resemble the changes caused by drug addiction.

28 Jun 2014

Autism Speaks awards more than $600,000 to scientists pursuing training in translational research

Autism Speaks, the world's leading autism science and advocacy organization, today announced it has awarded more than $600,000 in funding for six promising scientists pursuing academic training in translational research.

28 Jun 2014

Menopause-related changes in sex hormones linked to greater risk for heart disease

As hormone levels change during the transition to menopause, the quality of a woman's cholesterol carriers degrades, leaving her at greater risk for heart disease, researchers at the University of Pittsburgh Graduate School of Public Health discovered.

28 Jun 2014

AHA honors two Mount Sinai Health System experts as "Heart and Stroke Lifesavers"

The American Heart Association has honored two Mount Sinai Health System experts as "Heart and Stroke Lifesavers" for going above and beyond the call of duty in support of the AHA's mission to build lives free of cardiovascular diseases and stroke.

28 Jun 2014

Child maltreatment increases vulnerability to alcohol consumption when reaching adolescence

A study coordinated by Jorge Manzanares, Professor of Pharmacology at the University Miguel Hernández (UMH) in Elche (Spain), shows that child maltreatment, whatever its form, produces functional brain changes that increase vulnerability to alcohol consumption when reaching adolescence.

28 Jun 2014

Non-surgical gum disease treatment reduces thickness of wall of arteries

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

28 Jun 2014

First step toward new drugs that can transcend antibiotic resistance issues

Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that experts consider a serious threat to global health.

28 Jun 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

Research shows colon cancer survivors are more likely to experience pain in back, abdomen

Researchers from the University of Granada have discovered that colon cancer survivors are more likely to suffer future lesions related with pain in the back and lower abdomen than healthy individuals of the same gender and age.

27 Jun 2014

Therapy News and Research

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Complete analysis of regenerative medicine market

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

MagForce publishes operative highlights and financial results for fiscal year 2013

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

Modified classification system finds over one-third of knee replacements as inappropriate

Single gene defines difference between aggressive and non-aggressive forms of thymoma

New concussion therapy program for NFL members

Host-directed therapy: A new type of TB treatment

Targeting ASIC-related neurotransmission may lead to new therapies for treating drug addiction

Autism Speaks awards more than $600,000 to scientists pursuing training in translational research

Menopause-related changes in sex hormones linked to greater risk for heart disease

AHA honors two Mount Sinai Health System experts as "Heart and Stroke Lifesavers"

Child maltreatment increases vulnerability to alcohol consumption when reaching adolescence

Non-surgical gum disease treatment reduces thickness of wall of arteries

First step toward new drugs that can transcend antibiotic resistance issues

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Research shows colon cancer survivors are more likely to experience pain in back, abdomen

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News